News | Congenital Heart | March 03, 2016

L.A. Doctors Perform Rare Fetal Cardiac Intervention for First Time in Southern California

Doctors insert tiny device in fetal heart to normalize blood flow and strengthen newborn for open-heart surgery after birth

Children's Hospital Los Angeles, CHLA, in utero atrial septal stent procedure, Grayson

Image courtesy of Children's Hospital Los Angeles

March 1, 2016 — Last August, Children’s Hospital Los Angeles (CHLA) cardiologists confirmed the heart of a 27-week-old fetus suffered from a critical cardiac condition that prevented blood returning from the fetus’s lungs from circulating back into the body. They told the parents their child faced certain open-heart surgery after birth. Even worse, babies born with this very rare condition — hypoplastic left heart syndrome (HLHS) with restrictive atrial septum — have a 50 percent neonatal mortality rate.

But thanks to the expertise available at CHLA, the Davilas had another option — having their unborn child (now delivered and named Grayson) undergo a fetal cardiac intervention procedure in utero that would increase the odds of the child’s survival when the open-heart surgery took place. The procedure would be coordinated by fetal therapy specialists from the CHLA-USC Institute for Maternal-Fetal Health.

If all went well, Grayson would survive and undergo open-heart surgery performed by CHLA’s heart surgery team, led by cardiothoracic surgeon Vaughn Starnes, M.D., co-director of the CHLA Heart Institute.

“CHLA was the only institution I could find on the West Coast that offered my child the access to premium, state-of-the-art facilities and great care before and after his birth,” said Grayson’s father, Marco Davila.

On Sept. 9, the physicians gathered at CHA Hollywood Presbyterian Medical Center to perform what cardiologists describe as an “in utero atrial septal stent procedure” to open the atrium, allowing blood trapped in the lungs and left upper heart chamber of a HLHS fetus to flow back to the right side of the heart. The successful procedure was a first for the Institute for Maternal-Fetal Health and a first for a Southern California hospital.

The fetal interventionalist conducting the procedure was Ramen Chmait, M.D., director of Los Angeles Fetal Surgery, a branch of the CHLA-USC Institute for Maternal-Fetal Health. Chmait guided a thin needle into the mother’s womb and into the heart of the fetus. Pediatric interventional cardiologist Frank Ing, M.D., co-director of the CHLA Heart Institute, then deployed a stent device in the developing child’s heart. Ultrasound guidance (fetal echocardiogram) provided by CHLA fetal cardiologist Jay Pruetz, M.D., showed the way for both physicians.

“The work by the team demonstrated the state-of-the-art prenatal diagnosis and fetal heart therapy technology, based on a multi-disciplinary approach, available for fetuses with severe congenital heart defects,” said Ing, chief of the Division of Cardiology at CHLA. “We demonstrated that in utero procedures can ultimately alter the natural history and postnatal health outcomes to increase a child’s odds for survival. This expertise was brought together by a vision to provide these specialized interventions and top surgical care as no other institution can in Southern California.”

“Completing this highly specialized fetal intervention procedure contributed to Grayson’s ability to survive after his birth,” said Chmait, associate professor of clinical obstetrics and gynecology at the Keck School of Medicine of the University of Southern California. “It successfully strengthened his lungs so the surgeons could do their job after he was born.”

Everything about the procedure required special preparation. Incredibly small fetal microsurgery tools, including a 12-centimeter metal needle, and a tiny transcatheter metal stent that inflates to 2.8 millimeters across the atrial septum, were used to perform the procedure. The mother, Samantha Davila, received local anesthesia. The baby was anesthetized in the womb so there would be no ill-timed movements as the doctors worked.

Chmait used a thin (18-gauge) metal needle, called a cannula, to penetrate the mom’s stomach, guiding it into her uterus, through the amniotic cavity and into the fetus’s torso. The cannula was carefully finessed into the fetus’s heart (which is about the size of a small walnut), puncturing the atrial septum with the needle tip inside the fetus’s left atrium.

With the cannula stationed across the atrial septum, Ing then threaded a hair-thin wire (0.014 inches) down through the tube, the wire acting as a rail for Ing to gently maneuver a tiny, 8-millimeter-long stent across the septum. Ing mounted the stent onto a balloon catheter for delivery and used a predetermined amount of pressure to inflate the delivery balloon and expand the stent to open a pathway in the atrial septum. The team of doctors determined the stent was in good position by ultrasound imaging, and then deployed it by inflating the balloon catheter.

Once the stent was confirmed to be functioning, the balloon catheter was deflated and everything was removed from the baby and the mother, including the wire and needle. The stent remained in the heart to allow blood flow out of the left upper chamber, across the atrial septum, and back into circulation in the right side of the heart. The procedure itself took about 15 minutes once the fetus was in place. After 30 additional minutes of monitoring, the procedure was concluded.

During the remainder of the pregnancy, Samantha was followed closely to ensure the atrial stent was functioning well. The stent held up until the late third trimester, when it appeared to close down, providing little to no flow between the fetus’s upper heart chambers, Pruetz said. But in the interim, the lungs had been given time to strengthen and develop during a critical time window of gestation. Ten weeks after the stent procedure, Samantha gave birth via a planned cesarean section at Hollywood Presbyterian. Grayson was born on Nov. 19 at 8:29 a.m.

Following Grayson’s delivery, the closure of the atrial septum in Grayson’s heart prevented the lungs from delivering enough oxygenated blood back to his body. Consequently, Grayson was immediately transported next door to CHLA. There, a pediatric cardiothoracic surgery team was standing by to perform a full Norwood surgery, led by Starnes. Starnes began the operation just 90 minutes after birth, which is uncommon but was determined to be safe for Grayson because the stent procedure had successfully promoted lung development, enabling him to survive the invasive operation.

The Norwood surgery uses the right heart and pulmonary artery to become the main pathway for pumping blood to the body. Starnes removed the stent from Grayson’s heart and also performed a Sano modification using a tube to connect the right ventricle to the pulmonary artery as part of the Norwood procedure. “We were able to operate quickly because we were aware of his condition and Grayson’s lungs were strong enough,” Starnes explained. “This coordination of care between the fetal therapy team and CHLA surgeons was extraordinary, starting with the transcatheter fetal cardiac procedure, the monitoring during the pregnancy leading up to the birth, and the surgery.”

Grayson was discharged from CHLA on Dec. 14 and went home with his thrilled parents. “The health outcomes for children who receive the Norwood procedure at CHLA are considerably higher than the national average,” Starnes said. Grayson still has two additional heart surgeries ahead, the Glenn and the Fontan, procedures that route oxygen–poor blood directly to the lungs, leaving the right ventricle employed as the heart’s primary pumping chamber. Those operations will take place over the next six months and at 3 years of age, respectively.

For more information:

Related Content

Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.
Feature | September 11, 2017
September 11, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has sele
LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

Feature | Left Atrial Appendage (LAA) Occluders| September 07, 2017
September 7, 2017 — Closure of the left atrial appendage (LAA) during heart surgery protects the brain, according to
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices| September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
Siemens Healthineers Receives FDA Clearance for TrueFusion Structural Heart Disease Feature
Technology | Cardiovascular Ultrasound| September 06, 2017
The U.S. Food and Drug Administration (FDA) has cleared TrueFusion, a new cardiovascular application from Siemens...
Minneapolis Heart Institute Foundation Enrolls First Patient in TRILUMINATE Tricuspid Repair Trial
News | Heart Valve Technology| September 05, 2017
Minneapolis Heart Institute Foundation announced it has enrolled the first-in-the-world patient in a clinical study to...
Abbott Initiates U.S. Pivotal Study of Amplatzer Device for Patent Ductus Arteriosus
News | Congenital Heart| September 05, 2017
Abbott announced it has initiated a U.S. pivotal clinical study evaluating the safety and effectiveness of a modified...
World's First Successful 52-mm Transcatheter Tricuspid Valve Implantation Completed in Italy
News | Heart Valve Technology| August 31, 2017
NaviGate Cardiac Structures Inc. (NCSI) announced that its Gate catheter-guided tricuspid atrioventricular valved stent...
Sponsored Content | Videos | Heart Valve Technology| August 30, 2017
Azeem Latib, M.D., MBBCh, FCP, interventional cardiologist at Columbus Hospital in Milan, Italy, discusses the latest
Overlay Init